NCT04908852View on ClinicalTrials.gov

Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Acute Myeloid Leukemia (AML)
Interventions
OTHER

Blood Sample Collection - Observational Study

Blood samples will be collected at enrollment and week 4 and used in analyses to understand associations between metabolic function and symptom experiences.

OTHER

Symptom questionnaires - Observational Study

Symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Institute of Nursing Research (NINR)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT04908852 - Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML | Biotech Hunter | Biotech Hunter